Interview: Luis Almeida, CEO, Luzitin, Portugal
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Luzitin, S.A. is an early-stage pharmaceutical company focused on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases, thus contributing to the human wellness.
Luzitin emerged as a spin-off company from an R&D partnership between Bluepharma, S.A. and the University of Coimbra, Portugal. The Luzitin’s starting intellectual property is a series of new photosensitizing drugs licensed-in from the University of Coimbra. In March 2011, these new photosensitizers have been awarded the INVENTA Prize, which honoured the most relevant Portuguese invention of the 2001-2010 decade.
Luzitin’s shareholders are Bluepharma, S.A., a venture capital firm (Portugal Ventures, S.A.), and the inventors of the patented drugs. Luzitin’s headquarters are located at S Martinho do Bispo, Coimbra, Portugal. Luis Almeida, MD, PhD (Chief Executive Officer), Luis Arnaut, PhD (Chief Scientific Officer), and Sérgio Simões, PharmD, PhD (Chairman), compose the Management Team (MT). All have over 20 years of experience in their fields, and altogether they cover all disciplines involved in drug R&D from bench to bedside.
Luzitin’s long-term goal is to become a leader in PDT or PDx of cancer and other selected indications by providing innovative products and services, and partnering with other companies and public research institutions to bring new products to market.
Luzitin is committed to reach proof-of-concept clinical trials (phase II) and afterwards to negotiate licensing terms with a pharmaceutical company to further co-develop and co-market its compounds.
Contact:
Luzitin, SA
Edifício Bluepharma – Rua da Bayer – S. Martinho do Bispo
3045-016 Coimbra
PORTUGAL
Phone: +351 239 800 300
Fax: +351 239 800 333
www.luzitin.pt
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Oscar Gaspar, VP of the Confederation of Portuguese Industry (CIP), president of the Portuguese Association of Private Hospitalization and former secretary of state for health (2009-2011), provides an informative insight…
Portugal’s Minister for Science, Technology and Higher Education, Manuel Heitor, details his plan to bring Portuguese scientific and business practices above European averages. Collaboration across industries, increased public and private…
Salvador Lopez saw an opportunity in the summer of 2015 to create the first Portuguese affiliate for Mundipharma. Three years on, he reveals how their business model, company culture and…
Laurent Marionnet, director general of the French Chamber of Commerce in Portugal provides an overview of the Chamber’s activities, an intriguing insight into Portuguese success citing geopolitical factors and cultural…
Jose Aranda da Silva, the first President of INFARMED and an expert on the Portuguese healthcare sector, comments on the successes of the sector since the crisis and how SiNATS…
The iMM (Instituto de Medicina Molecular) is a leading Portuguese private non-profit research institute that offers a vibrant scientific environment, aiming to nurture innovative ideas in basic, clinical and translational…
ARSLVT exists to make sure that people living in the Lisbon and Tagus Valley have access to quality health care, adapting the resources available to the region’s health needs and…
Maria-Ceu Machado, president of INFARMED the National Authority of Medicines and Health Products, stresses the importance of healthcare restructuring and streamlining work practices in Portugal. In her first year as…
When Indian generics company Aurobindo established itself in Portugal in 2010, the affiliate was faced with some difficult choices. As the latest company to enter the Portuguese generic market, Aurobindo…
David Malta and Daniela Couto, Co-founders of Cell2B, discuss the company’s origins and plans to achieve market authorization, and what makes the fledgling company the partner of choice. What…
CPH Pharma was the oldest running pharmaceutical company in Portugal until its acquisition by Grupo Ferrer in 2008. Since then, the company has continued to thrive in the marketplace despite…
Biopremier is a Portuguese biotech company specializing in DNA tests, particularly in the agri-food area. The company’s chairman, Pedro Fernandes Antunes, speaks about the capacity of Portugal’s biotech sector and…
See our Cookie Privacy Policy Here
